The biochemical response to food intake must be precisely regulated. Because ingested sugars and fats can feed into many anabolic and catabolic pathways 1 , how our bodies handle nutrients depends on strategically positioned metabolic sensors that link the intrinsic nutritional value of a meal with intermediary metabolism. Here we describe a subset of immune cells-integrin β7 + natural gut intraepithelial T lymphocytes (natural IELs)-that is dispersed throughout the enterocyte layer of the small intestine and that modulates systemic metabolism. Integrin β7 − mice that lack natural IELs are metabolically hyperactive and, when fed a high-fat and high-sugar diet, are resistant to obesity, hypercholesterolaemia, hypertension, diabetes and atherosclerosis. Furthermore, we show that protection from cardiovascular disease in the absence of natural IELs depends on the enteroendocrine-derived incretin GLP-1 2 , which is normally controlled by IELs through expression of the GLP-1 receptor. In this metabolic control system, IELs modulate enteroendocrine activity by acting as gatekeepers that limit the bioavailability of GLP-1. Although the function of IELs may prove advantageous when food is scarce, present-day overabundance of diets high in fat and sugar renders this metabolic checkpoint detrimental to health.
We next tested whether the beneficial metabolic alterations in β7 −/− mice were sustained in the context of the 'metabolic syndrome' component cluster 10 . β7 −/− mice that were fed a diet high in fat, sugar and sodium (HFSSD) remained relatively lean, in contrast to wild-type controls, which became obese ( Fig. 2a ). Both inguinal white adipose tissue (iWAT) and perigonadal white adipose tissue (pWAT) were heavier in wild-type mice than in β7 −/− mice, but other tissue weights remained similar ( Fig. 2b ). Furthermore, adipocytes in iWAT and pWAT were larger in wild-type mice than in β7 −/− mice ( Fig. 2c-e ). Flow cytometry of both iWAT and pWAT showed that fewer Ly-6C high monocytes, neutrophils and macrophages had accumulated in β7 −/− mice, indicating that β7 −/− mice were protected from obesity-associated inflammation 11, 12 (Extended Data Fig. 2a, b) . In contrast to wild-type control mice, β7 −/− mice did not develop hypertension ( Fig. 2f ) and-similar to observations made in β7 −/− mice that were on a chow diet-β7 −/− mice that were fed a HFSSD remained more glucose-tolerant than wild-type mice ( Fig. 2g and Extended Data Fig. 2c, d) , indicating that β7 −/− mice were protected against the adverse metabolic consequences of a high-fat diet.
Because β7 −/− mice had a higher metabolism and exhibited fewer metabolic syndrome components, we tested whether they had lower rates of atherosclerosis, which is a chronic, lipid-driven inflammatory disease 13 . We generated Ldlr −/− chimaeras reconstituted with bone marrow from either β7 −/− (bmβ7 −/− ) or wild-type (bmβ7 +/+ ) mice and found that Ldlr −/− mice with β7 −/− bone marrow (bmβ7 −/− Ldlr −/− ) that were fed a diet high in cholesterol (HCD) had considerably lower levels of plasma total cholesterol than controls (bmβ7 +/+ Ldlr −/− ) ( Fig. 3a and Extended Data Fig. 2e ). The bmβ7 −/− Ldlr −/− mice had lower levels of very-low-density lipoprotein, intermediate-density lipoprotein and low-density lipoprotein, but similar levels of high-density lipoprotein (Fig. 3b ). bmβ7 −/− Ldlr −/− mice gained weight in a similar manner to bmβ7 +/+ Ldlr −/− controls (Extended Data Fig. 2f ), yet tended to excrete more cholesterol (Extended Data Fig. 2g ). Moreover, bmβ7 −/− Ldlr −/− mice had smaller aortic root lesions (Fig. 3c) , with a reduction of around 50% in plaque size and volume ( Fig. 3d, e ). These changes were driven by differences in the size of the necrotic core (Extended Data Fig. 2h -j) and the number of leukocytes (Fig. 3f ), the latter of which was independent of β7-mediated recruitment (Extended Data Fig. 3a, b ). Because hypercholesterolaemia induces leukocytosis 14 , which is a cardiovascular risk factor 15 , we also analysed the number of leukocytes in the blood and found fewer circulating Ly-6C high and Ly-6C low monocytes in bmβ7 −/− Ldlr −/− mice fed a HCD (Fig. 3g ), but not in bmβ7 −/− Ldlr −/− mice fed a chow diet (Extended Data Fig. 3c ). Similar to experiments obtained using β7 −/− mice, we noted improved glucose tolerance in the bmβ7 −/− Ldlr −/− chimaeras (Extended Data Fig. 3d ). We also generated β7 −/− Ldlr −/− mice. Following assessment of metabolic functions, which were similar to those in β7 −/− mice,
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we noted that β7 −/− Ldlr −/− mice had lower levels of plasma cholesterol, smaller aortic root lesions and fewer aortic leukocytes after HCD (Extended Data Fig. 4a-d ). Finally, we injected anti-integrin β7 antibodies into Ldlr −/− mice and found that these mice had improved glucose tolerance and attenuated atherosclerosis (Extended Data Fig. 4e -g). These data show that integrin β7 deficiency protects against atherosclerosis.
Next, we investigated which cells account for our findings. Intraepithelial lymphocytes that reside in the small intestine had the highest integrin β7 expression ( Fig. 4a ), in agreement with studies that have shown that integrin β7 guides leukocytes to the gut 16, 17 . Although the intestinal intraepithelium had fewer CD3 + cells in β7 −/− mice (Extended Data Fig. 5a ), we nevertheless analysed the relative ability of β7 + cells to enter tissues (Extended Data Fig. 5b ). The blood contained β7 −/− and wild-type cells in similar proportions ( Fig. 4b ) and-although many tissues accumulated β7 −/− and wild-type cells in similar, albeit varied, proportions-considerably fewer β7 −/− cells accumulated in the gut and particularly in the small intestine intraepithelium ( Fig. 4b and Extended Data Fig. 5b ). These findings therefore confirm that integrin β7 directs leukocytes to the gut.
We show that the leukocytes that rely on integrin β7 influx to the gut are αβ and γδ T cells ( Fig. 4c) , B cells and myeloid cells (Extended Data Fig. 5c ). Notably, β7 −/− mice had similar numbers of leukocytes as wild-type mice in metabolically important organs such as the liver and pancreas (Extended Data Fig. 5d , e). Although T cells were the most numerous integrin β7-dependent population that was assessed in the gut, we nevertheless tested which of the three populations (αβ and γδ T cells, B cells or myeloid cells) mediated the metabolic effects. We therefore generated five different mixed chimeric groups of mice (β7 −/− wild-type, β7 −/− Tcrb −/− (hereafter β7 −/− βTCR −/− ), β7 −/− Tcrd −/− (hereafter β7 −/− γδTCR −/− ), β7 −/− Ighm tm1Cgn (hereafter β7 −/− μMT) and β7 −/− Ccr2 −/− ) on a wild-type background and performed a glucose-tolerance test to screen for the metabolic phenotype. We found that specific absence of integrin β7 on either αβ (β7 −/− βTCR −/− ) or γδ (β7 −/− γδTCR −/− ) T cells improved glucose tolerance ( Fig. 4d ), whereas no changes were found in the other mixed chimaeras (Extended Data Fig. 5f ). Both Itgae −/− and Ccr9 −/− mice 18,19 showed a similar improvement in glucose tolerance ( Fig. 4e ). Moreover, given the importance of B cells for gut homeostasis 20,21 , we analysed the contribution of this lymphocyte population in more detail, but found no differences in glucose tolerance, cholesterolaemia or atherosclerosis (Extended Data Fig. 6 ), indicating that β7-dependent B cells do not contribute to the metabolic phenotype. These data show that intraepithelial αβ and γδ T cells regulate systemic metabolism.
In response to dietary nutrients, enteroendocrine L-cells in the gut produce the incretin hormone GLP-1, which induces postprandial pancreatic insulin secretion and exerts glucose control 22, 23 . GLP-1 mediates various other beneficial effects on metabolism, while its analogue improves cardiovascular outcomes in patients with diabetes 24, 25 . We found that bmβ7 −/− Ldlr −/− mice that were fed a HCD had higher levels of fasting GLP-1 in the plasma (Fig. 4f) , along with increased gut Gcg mRNA levels (Fig. 4g ). In addition, β7 −/− mice had increased levels of GLP-1 compared to wild-type mice that were fed chow or a HFSSD (Extended Data Fig. 7a, b ). To test whether αβ and γδ T cells controlled the bioavailability of GLP-1, we measured the expression of the GLP-1 receptor in gut leukocytes and found that natural αβ and γδ T cells in wild-type mice showed abundant expression of the GLP-1 receptor, consistent with data from Immgen (http://www.immgen.org/) and a previous study 26 (Fig. 4h ). By contrast, the guts of β7 −/− mice were relatively deficient in expression of the GLP-1 receptor, containing fewer and mostly Glp1r low T cells (Extended Data Figs. 5a, 7c, d).
These results indicate that loss of Glp1r high natural IELs is associated with increased plasma levels of the ligand (GLP-1), an observation that is consistent with previous studies that show increased levels of GLP-1 in Glp1r −/− mice 27 .
To determine whether loss of the GLP-1 receptor on IELs protects against atherosclerosis through increased systemic levels of GLP-1, we generated mixed chimaeras (bmGlp1r −/− β7 −/− ; Fig. 4i ) on a Ldlr −/− background. After performing quality-control experiments (Extended Data Figs. 7e, 8a-e), we found that bmGlp1r −/− β7 −/− Ldlr −/− mice had increased concentrations of GLP-1 ( Fig. 4j ), were more glucose tolerant ( Letter reSeArCH apparent between Glp1r −/− and wild-type chimaeras on a wild-type (that is, not Ldlr −/− ) background, although we did see differences in the Glp1r −/− β7 −/− mixed chimaeras (Extended Data Fig. 8f -i). By contrast, we found attenuated atherosclerosis in Ldlr −/− mice that received the GLP-1 receptor agonist exendin-4 (Extended Data Fig. 8j , k), consistent with previous data generated in Apoe −/− mice 28, 29 .
Finally, we reasoned that Glp1r high IELs may be limiting the bioavailability of GLP-1 by several non-mutually exclusive mechanisms. First, we found that β7 −/− mice had an increased number of GLP-1producing L-cells, suggesting that Glp1r high IELs may be controlling GLP-1 production (Extended Data Fig. 9a ). Second, we confirmed that the GLP-1 receptor in Glp1r high IELs is functional, can bind to, capture (Extended Data Fig. 9b ) and control the bioavailability of GLP-1 (Extended Data Fig. 9c-f ). These results indicate that the loss of the GLP-1 receptor in IELs triggers a systemic response and limits development of cardiovascular disease through regulation of GLP-1 availability (Extended Data Fig. 10 ).
In the gut, T cells help to maintain barrier integrity via various pleiotropic functions. Here we identified β7 + IELs as critical gatekeepers of dietary metabolism. Although the evolution of regulatory mechanisms that sense nutrient availability and regulate energy disposal and storage should offer a survival advantage over organisms that indiscriminately metabolize and expend their ingested energy, such mechanisms may have adverse effects if they become too dominant. Future studies will therefore need to investigate the function of IELs in numerous contexts to determine whether specific targeting of this population or its products can mitigate cardiometabolic diseases.
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Mice. C57BL/6J (wild-type mice), B6.SJL-Ptprc a Pepc b /BoyJ (CD45.1 + ), Itgb7 tm1Cgn (β7 −/− ), Ldlr tm1Her (Ldlr −/− ), Tcrb tm1Mom (βTCR −/− ), Tcrd tm1Mom (γδTCR −/− ), Ccr2 tm1Ifc (Ccr2 −/− ), Ighm tm1Cgn (μMT), Ccr9 tm1Lov (Ccr9 −/− ), Itgae tm1Cmp (Itgae −/− ), and C57BL/6-Tg(UBC-GFP)30Scha/J (GFP + ) mice were purchased from The Jackson Laboratory. Glp1r −/− mice on the C57BL/6 background were bred in-house as described 30 . Unless otherwise indicated, age-and sex-matched animals were used starting at 8-12 weeks of age. Female mice were used for experiments in Fig. 1h , k, l, 4e, and Extended Data Figs. 1g, 4c, d . A mixture of sexes was used in Fig. 1j . Male mice were used in all other experiments. Investigators were blinded to group allocation during data collection and analysis. Where appropriate, animals were randomly assigned to interventions. All protocols were approved by the Animal Review Committee at Massachusetts General Hospital (protocols 2011N000035 and 2015N000044) and were in compliance with relevant ethical regulations. Animal models and in vivo interventions. Diet. For studies on metabolic syndrome, wild-type and β7 −/− mice were fed a HFSSD (Research Diets D12331). For studies on atherosclerosis, bone marrow chimaeras on the Ldlr −/− background or double knockouts were fed a HCD (Research Diets D12108C). HFSSD-fed and HCD-fed mice were single-or group-housed on a 12-h:12-h light:dark cycle at 22 °C with free access to food and water. HFSSD-fed mice were maintained under these conditions for 21 weeks and HCD-fed mice for 14 weeks. For studies on glucose tolerance in thermoneutrality, wild-type mice and β7 −/− mice were housed for 3 days in a 12-h:12-h light:dark cycle at 30 °C with free access to food and water. For studies on microbiota, mice were treated with an antibiotics cocktail (0.1% ampicillin, 0.1% metronidazole, 0.05% vancomycin and 0.1% neomycin) in drinking water for 4 weeks and an equal number of 8-week-old wild-type and β7 −/− mice with the same day of birth were co-housed for 4 weeks. Bone marrow transplantation. Naive C57BL/6 or Ldlr −/− mice were lethally irradiated (950 cGy) and reconstituted with indicated bone marrow cells to generate different chimaera groups: Anti-integrin β7 antibody treatment. Ldlr −/− mice on a HCD were treated with anti-integrin β7 antibodies (FIB504, BioxCell) or IgG isotype control (2A3, BioxCell) by intraperitoneal injection for 14 weeks for quantification of atherosclerotic plaque size after euthanasia (500 μg per mouse per week). Glp1r agonist treatment. Ldlr −/− mice were treated with the Glp1r agonist exendin-4 (Abcam) at a dose of 100 μg per kg per day via osmotic minipumps (Alzet). After 8 weeks on a HCD, mice were euthanized for atherosclerotic lesion quantification. Metabolic measurements. CLAMS. A comprehensive laboratory animal monitoring system (CLAMS, The Columbus Instruments) was used at the Joslin Diabetes Center Animal Physiology Core to simultaneously measure a series of metabolic parameters including energy expenditure (heat production), oxygen consumption V ( ) O 2 , carbon dioxide production V ( ) CO 2 , respiratory exchange ratio, food consumption and locomotor activity levels. Blood pressure measurements. Systolic and diastolic blood pressures were measured using a non-invasive tail-cuff system (Kent Scientific). Mice were initially acclimatized to the instrument for three consecutive days before the measurements.
[ 18 F]FDG PET/CT. The uptake and distribution of glucose in vivo were determined by [ 18 F]FDG and non-invasive, high-resolution PET/CT imaging and ex vivo biodistribution. In brief, mice were anaesthetized with isoflurane and injected intravenously through the tail vein with around 200 μCi of tracer diluted to a final volume of 150 μl in isotonic saline. Following a 60-min absorption period, mice were imaged on a Siemens Inveon small-animal integrated PET/CT scanner. The CT was acquired over 360 projections using a 80 kV, 1 μA X-ray tube operating at 80 kilovoltage peak (kVp) and 500 μA on a CMOS detector and reconstructed using a modified Feldkamp cone beam reconstruction algorithm (COBRA, Exxim Computing Corporation). A 20-min PET image was acquired and reconstructed using the ordered subsets expectation maximization followed by maximum a posteriori. Regions of interest were manually drawn for standard uptake value calculations. After imaging, animals were euthanized and tissues were collected for biodistribution analysis using gamma well counting on a 20% window on the 511 keV photopeak (Wizard2, PerkinElmer). [ 18 F]FDG levels were normalized to the weight of resected tissue and expressed as the percentage injected dose per gram tissue weight. Glucose-and insulin-tolerance tests. For glucose-and insulin-tolerance tests, overnight-fasted mice were injected intraperitoneally or by oral gavage with glucose (2 g per kg body weight) or injected intraperitoneally with insulin (0.75 U per kg body weight). Blood glucose levels were measured at the basal level and at 15, 30, 60, 90 and 120 min after glucose or insulin administration using One Touch Ultra2 Blood Glucose Meter (OneTouch, LifeScan). Fat-tolerance test. Overnight-fasted mice were injected intraperitoneally with 200 μl 20% Intralipid (vol/vol) fat emulsion (Sigma, MA), and blood that was drawn from the retroorbital plexus at the indicated time points for triglyceride measurement using the L-Type Triglyceride M kit (Wako Diagnostics, VA). To measure hepatic lipid export, overnight-fasted mice were injected with 1 g per kg poloxamer 407 (Pluronic F-127, Sigma) and plasma was collected at the indicated time points for triglyceride analysis. Fat absorption test. To measure fat absorption in the gut, overnight-fasted mice were injected intraperitoneally with 1 g per kg poloxamer 407. After 1 min, the mice were gavaged with 0.4 ml corn oil. Plasma was collected at baseline as well as at the indicated time points after gavage for analysis of triglyceride levels. FPLC. Mice were fasted for 12-16 h overnight before blood samples were collected by retro-orbital venous plexus puncture, after which plasma was separated by centrifugation. The lipid distribution in plasma lipoprotein fractions was assessed by fast-performed liquid chromatography (FPLC) gel filtration with 2 Superose 6 HR 10/30 columns (Pharmacia Biotech). Total plasma cholesterol in each fraction was enzymatically measured (Wako Pure Chemicals). Cholesterol. Plasma was collected from overnight-fasted or non-fasted mice that were fed a HCD for 14 weeks, and plasma total cholesterol was determined by a Cholesterol E kit (Wako Diagnostics). Gut permeability test. Overnight-fasted mice were administered through oral gavage with fluorescein isothiocyanate (FITC)-dextran (Sigma-Aldrich) at a dose of 12 mg per mouse, and plasma was collected 4 h later for fluorescence intensity measurement. A mouse model of colitis in which a mouse was treated with dextran sulfate sodium salt (36-50 kDa, MP Biomedicals) in drinking water for 6 days was used as a positive control for gut barrier disruption. Cells. Cell collection. Peripheral blood was collected by retro-orbital bleeding and red blood cells were lysed in RBC lysis buffer (Biolegend). Aortas were excised after PBS perfusion (Thermo Fisher Scientific), minced and digested with 450 U ml −1 collagenase I, 125 U ml −1 collagenase XI, 60 U ml −1 DNase I and 60 U ml −1 hyaluronidase (Sigma-Aldrich) in PBS for 40 min at 37 °C. Total viable cell numbers were counted using trypan blue (Cellgro, Mediatech). Small-intestine IELs were isolated as follows: after excision of the small intestine, the Peyer's patches were removed under a microscope and the gut was cut open longitudinally to wash off the lumen contents in HBSS buffer. The gut was then cut into 1-2-cm pieces and subjected to 3× dissociation in EDTA-containing buffer (7.5 mM HEPES, 2% FCS, 2 mM EDTA, 10,000 U ml −1 penicillin-streptomycin, 50 μg ml −1 gentamycin in HBSS; all Thermo Fisher Scientific) in a shaker at 37 °C for 15 min. After dissociation the IELs were collected by filtering the lamina propria through a mesh. Cell sorting. The IEL flow through after dissociation was further subjected to Percoll (GE Healthcare Bio-Sciences) grade centrifugation to remove the mucus. Single-cell suspensions of IELs from indicated animals were then stained to identify indicated cell populations. Cells were sorted on a FACS Aria II cell sorter (BD Biosciences) directly into either RLT buffer for subsequent RNA isolation or into collection medium for ex vivo manipulations. Flow cytometry. Single-cell suspensions were stained in PBS supplemented with sterile 2% FBS and 0.5% BSA. The following monoclonal antibodies were used for flow cytometric analysis: anti-integrin β7 (clone FIB27), anti-CD45 (30-F11), anti-CD45.1 (clone A20), anti-CD45.2 (clone 104), anti-CD3 (clone 17A2), anti-CD90.2 (clone 53-2.1), anti-CD19 (clone 6D5), anti-B220 (clone RA3-6B2), anti-NK1.1 (clone PK136), anti-Ly-6G (clone 1A8), anti-Ly-6C (AL-21), anti-MHCII (clone AF6-120.1), anti-F4/80 (clone BM8), anti-CD11b (clone M1/70), anti-CD5 (clone 53-7.3), anti-βTCR (clone H57-597), anti-γδTCR (clone GL3), anti-CD326 (clone G8.8), anti-IgA (C10-3), anti-IgD (11-26c.2a), anti-CD115 (clone AFS98), and anti-CX3CR1 (clone SA011F11). Antibodies were all purchased from BioLegend except anti-IgA (BD Biosciences). Viable cells were identified as unstained with Zombie Aqua (Biolegend). Cells were defined as: (i) Ly-6C high monocytes (CD45 + Lin − CD11b + F4/80 − Ly-6C high ); (ii) neutrophils
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Extended Data Fig. 2 | Effects of integrin β7 deficiency on obesity, cholesterolaemia and atherosclerosis. a, Representative flow cytometry plots gated on CD45 + non-T and B (TB) leukocytes and quantification of Ly-6C high monocytes, neutrophils and macrophages (Mφ) in iWAT of wild-type and β7 −/− mice fed a HFSSD for 5 months. n = 5 wild-type mice; n = 4 β7 −/− mice; *P < 0.05, two-tailed Mann-Whitney U-test. b, Representative flow cytometry plots and quantification of Ly-6C high monocytes, neutrophils and macrophages in pWAT of wild-type and β7 −/− mice fed a HFSSD for 5 months. n = 5 wild-type mice; n = 4 β7 −/− mice; *P < 0.05, two-tailed Mann-Whitney U-test. c, Plasma glucose levels measured in overnight-fasted animals fed a HFSSD for 5 months. n = 10 wild-type mice; n = 7 β7 −/− mice; ***P < 0.001, two-tailed Mann-Whitney U-test. d, Insulin levels measured in overnight-fasted animals fed a HFSSD for 5 months. n = 9 wild-type mice; n = 8 β7 −/− mice; *P < 0.05, two-tailed Mann-Whitney U-test. e, Fasting plasma total cholesterol levels of mice fed a chow diet. n = 6 mice per group. f, Body weight changes during a 14-week HCD diet of bmβ7 +/+ Ldlr −/− and bmβ7 −/− Ldlr −/− mice. n = 5 mice per group. g, Faecal cholesterol levels in bmβ7 +/+ Ldlr −/− and bmβ7 −/− Ldlr −/− mice after a 14-week HCD diet. n = 5 mice per group; P = 0.09, two-tailed unpaired Student's t-test. h-j, Representative images and histological quantification of macrophages (h), collagen content and necrotic core size (i) and smooth muscle cell content (j) of bmβ7 +/+ Ldlr −/− and bmβ7 −/− Ldlr −/− mice after 14 weeks on a HCD. n = 5 mice per group; **P < 0.01, ***P < 0.001, two-tailed unpaired Student's t-test. Data are mean ± s.e.m.
Extended Data Fig. 3 | Effects of integrin β7 deficiency on myeloid cells and glucose tolerance. a, Ldlr −/− mice were lethally irradiated and reconstituted with bone marrow mixtures of wild-type and β7 −/− mice (1:1) and fed a chow diet or HCD for 14 weeks. b, The aortic leukocytes from different origins were analysed by flow cytometry. n = 4 mice for both HCD recipients and chow recipients. c, Ly-6C high and Ly-6C low monocyte numbers in blood (n = 3 wild-type mice; n = 5 β7 −/− mice), bone marrow (n = 3 wild-type mice; n = 5 β7 −/− mice) and spleen (n = 6 mice per group) of wild-type and β7 −/− mice fed a chow diet. d, bmβ7 +/+ Ldlr −/− and bmβ7 −/− Ldlr −/− mice fed a HCD were subjected to an intraperitoneal glucose-tolerance test. n = 5 mice per group; *P < 0.05, two-tailed Mann-Whitney U-test. Data are mean ± s.e.m.
Extended Data Fig. 5 | Integrin β7 guides leukocytes to gut intraepithelium. a, Top, representative histology staining for CD3 in small intestines of wild-type and β7 −/− mice. Bottom, quantification of CD3 + cells in each villus (more than 15 villi were counted for each mouse). ***P < 0.001, two-way ANOVA. b, Schematic of the competitive transfer experiments. Mice (CD45.2 + ) were lethally irradiated and transplanted with a 1:1 ratio mix of GFP + β7 −/− bone marrow cells and CD45.1 + wild-type bone marrow cells. The chimerism in different tissues was normalized to the ratio in blood. n = 5 mice. c, Representative flow cytometry plots and quantification of B cells and myeloid cells in mice depicted in b. n = 5 biologically independent recipients. d, Quantification of γδT cells in the liver. n = 3 wild-type mice; n = 4 β7 −/− mice. WBC, white blood cells. e, Quantification of γδT cells in the pancreas. n = 4 wild-type mice; n = 5 β7 −/− mice. f, Wild-type mice were lethally irradiated and reconstituted with bone marrow cell mixtures of β7 −/− and wild-type (β7 −/− :wild-type cells, 1:1 ratio) or β7 −/− and indicated knockout mice (β7 −/− :knockout cells, 1:1 ratio). The indicated mixed chimaeras that specifically lack intestinal B cells (β7 −/− μMT) or myeloid cells (β7 −/− Ccr2 −/− ) were subjected to oral glucose-tolerance tests and the AUCs are shown. n = 5 mice per group for β7 −/− wild-type and β7 −/− μMT mice; n = 4 mice per group for β7 −/− wild-type and β7 −/− Ccr2 −/− mice. Data are mean ± s.e.m.
Extended Data Fig. 7 | Integrin β7 deficiency and GLP-1 . a, Plasma total GLP-1 levels after overnight fasting and 15 min after oral glucose load (2 g per kg body weight) in wild-type and β7 −/− mice that were fed a chow diet. Total GLP-1 fasting: n = 7 mice per group; total GLP-1 after oral glucosetolerance test (OGTT) 15 min: n = 7 wild-type mice; n = 6 β7 −/− mice. b, Plasma total GLP-1 levels after 5 months of a HFSSD. Total GLP-1 fasting: n = 7 mice per group; total GLP-1 oral glucose-tolerance test 15 min: 6 mice per group. c, Representative flow cytometry plots of smallintestinal IELs from wild-type and β7 −/− mice. d, Glp1r mRNA levels in sorted different IEL subsets from wild-type and β7 −/− mice. n = 4 wildtype mice; n = 5 β7 −/− mice. e, Wild-type mice were lethally irradiated and transplanted with a 1:1 bone marrow mixture of wild-type and GFP + or Glp1r −/− and GFP + . The chimerism in different tissues was analysed by comparing the percentage of GFP + leukocytes normalized to wild-type GFP + blood leukocytes. n = 4 mice per group. Data are mean ± s.e.m. *P < 0.05, ***P < 0.001. All P values from two-tailed unpaired Student's t-tests.
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